Description of the design of three recent phase III clinical trials incorporating fluoroquinolone antibiotics in treatment-shortening regimens for pulmonary.

Slides:

Advertisements

Similar presentations

The TB Alliance-Bayer Moxifloxacin Deal

Advertisements

TREATMENT OF TUBERCULOSIS, 2003

New drugs and regimens for TB: 2015 update

TB new treatments and new methodological challenges Dr Corinne Merle.

End TB Strategy HCW with cough since January. Seen at government clinic thrice with no sputum/CXR. Diagnosed TB in May only.

Mutant Prevention Concentration and the Selection Window Hypothesis Karl Drlica, Xilin Zhao, and Tao Lu Public Health Research Institute Newark, NJ.

PanACEA Studies: Phase I Phase IIa Phase IIb Phase III Q203 BTZ043

Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.

Pr Ali Ben Kheder The First annuel conference of LATA 24 March Beyrouth.

Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis UZ-UCSF ARD April 08, 2016 W.Samaneka MBChB, MSc Clin Epi, Dip HIV Man.

Evaluation of a Standardized Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB (ST REAM) Nehemiah Nhando UZ-UCSF ANNUAL RESEARCH DAY.

Treatment for Multi-drug Resistant TB

STREAM Trials Andrew Nunn MRC Clinical Trials Unit at UCL

Dose and range (mg/kg body weight)

Treatment algorithm for tuberculosis

Treatment algorithm for tuberculosis

Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm S.O. Simons, T. van der Laan,

Stratified medicine in the treatment of TB

STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.

Concepts in the pathogenesis of idiopathic pulmonary fibrosis (IPF).

Quit rate (7-day point prevalence) for long-term nicotine replacement therapy users in the varenicline and placebo groups from weeks 2 to 52, verified.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial Martin J Boeree, PhD, Norbert.

Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali M.

The correlation between Mycobacterium growth indicator tube (MGIT) time to culture positivity (TTP) and bacterial load count by molecular bacterial load.

Schematic representation of the potential clinical courses of idiopathic pulmonary fibrosis. Schematic representation of the potential clinical courses.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

M.R. Jacobs Clinical Microbiology and Infection

Timeline of approval of therapies for pulmonary arterial hypertension.

Tuberculosis drug-resistance in Lisbon, Portugal: a 6-year overview

T. Schön, P. Miotto, C.U. Köser, M. Viveiros, E. Böttger, E. Cambau

Diagnostic applications of metabolic dysregulation in pulmonary hypertension. Diagnostic applications of metabolic dysregulation in pulmonary hypertension.

Probability of death as a function of the number of months after randomisation in the National Emphysema Treatment Trial comparing medical therapy (––––)

Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary.

Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.

Profile of Pseudomonas aeruginosa resistance by country and antibiotic

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

Mean change from baseline in 6-min walking distance (6MWD) in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial.

Kaplan–Meier curves for the probability of a first adjudicated primary end-point event in the AMBITION trial, suggesting that the primary outcome events.

Treatment of Drug Resistant TB - Questions

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

Number of ventilator-associated pneumonia (VAP) patients with newly isolated micro-organisms from endotracheal aspirates after initiation of antibiotic.

Model for the association between pathological features, physiological alterations and their association with pathological and clinical features. Model.

Duration of antibiotic therapy according to clinical pulmonary infection score in a randomised trial of an antibiotic discontinuation policy for clinically.

Pulmonary arterial hypertension specific medication use at enrolment among previously diagnosed patients. 184 (7%) of patients were not on a prostaglandin,

Cumulative survival estimates for the subgroup of 127 patients with ventilator-associated pneumonia caused by nonfermentative Gram-negative bacilli according.

The effect of inhaled tiotropium (18 μg once daily) on the improvement in treadmill exercise endurance time in patients with chronic obstructive pulmonary.

Impact of dose adjustment in case of adverse drug reaction (ADR; includes dose interruption and/or reduction). a) No dose adjustment and b) dose adjustment.

Schematic diagram of the recently described concept of “systems medicine” [93], which includes genetic characterisation, cell biology and physiology, imaging.

Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble.

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Representative pressure tracings of a) pulmonary arterial pressure and b) pulmonary arterial wedge pressure (PAWP). Representative pressure tracings of.

The “route to quit” model, which indicates the contribution of different ways of quitting to overall rates of smoking cessation. #: in most cases nicotine.

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

Schematic diagram of the shared subgroups between asthma and chronic obstructive pulmonary disease (COPD). Schematic diagram of the shared subgroups between.

Effect of omalizumab (n = 209) on a) clinically significant and b) severe exacerbation rates, compared with placebo (n = 210). #: adjustment due to a pre-study.

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Reduction in craving expressed as area under the curve during 60 min for a) Nicorette 4 mg gum (♦), mouth spray (▴), lozenge (•) and placebo lozenge (▪);

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Potential protocol for the treatment of pulmonary embolism (PE), incorporating direct oral anticoagulants (OACs). Potential protocol for the treatment.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Calcium and vitamin D metabolism.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Description of the design of three recent phase III clinical trials incorporating fluoroquinolone antibiotics in treatment-shortening regimens for pulmonary tuberculosis: REMoxTB [9], RIFAQUIN [10] and OFLOTUB [11]. Description of the design of three recent phase III clinical trials incorporating fluoroquinolone antibiotics in treatment-shortening regimens for pulmonary tuberculosis: REMoxTB [9], RIFAQUIN [10] and OFLOTUB [11]. Note that moxifloxacin/rifapentine 900 mg was administered twice weekly and moxifloxacin/rifapentine 1200 mg was administered weekly. H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; M: moxifloxacin; Rp: rifapentine (with a subscript defining dose); G: gatifloxacin; ep, mp, rp and hp: placebos for ethambutol, moxifloxacin, rifampicin and isoniazid, respectively; LJ: Lowenstein–Jensen; MGIT: Mycobacteria Growth Indicator Tube. Stephen H. Gillespie Eur Respir Rev 2016;25:19-28 ©2016 by European Respiratory Society